These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 12931274

  • 1. Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease.
    Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Crespillo-Gómez C, Berg J.
    Horm Metab Res; 2003 Jul; 35(7):427-33. PubMed ID: 12931274
    [Abstract] [Full Text] [Related]

  • 2. Serum cytokines levels in Graves' disease.
    Al-Humaidi MA.
    Saudi Med J; 2000 Jul; 21(7):639-44. PubMed ID: 11500727
    [Abstract] [Full Text] [Related]

  • 3. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
    Balázs C, Farid NR.
    Acta Med Hung; 1991 Jul; 48(1-2):3-11. PubMed ID: 1813855
    [Abstract] [Full Text] [Related]

  • 4. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM, Prummel MF, Wiersinga WM.
    Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
    [Abstract] [Full Text] [Related]

  • 5. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J.
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [Abstract] [Full Text] [Related]

  • 6. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
    Glossop JR, Dawes PT, Nixon NB, Mattey DL.
    Arthritis Res Ther; 2005 Nov; 7(6):R1227-34. PubMed ID: 16277675
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP, Liljeström M, Laiho K, Tiitinen S, Kaarela K, Hurme M.
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [Abstract] [Full Text] [Related]

  • 8. Human soluble tumor necrosis factor receptor I (sTNF-RI) and interleukin-I receptor antagonist (IL-I Ra) in different stages of acute rheumatic fever.
    Kütükçüler N, Karaca NE, Sözeri BY, Koturoğlu G, Kurugöl Z, Ozyürek RA, Aksu G.
    Anadolu Kardiyol Derg; 2008 Apr; 8(2):139-42. PubMed ID: 18400635
    [Abstract] [Full Text] [Related]

  • 9. Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.
    Bodlaj G, Berg J, Pichler R, Sailer T, Biesenbach G.
    J Nephrol; 2004 Apr; 17(1):112-7. PubMed ID: 15151267
    [Abstract] [Full Text] [Related]

  • 10. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I.
    Mediators Inflamm; 2005 Aug 14; 2005(3):171-4. PubMed ID: 16106104
    [Abstract] [Full Text] [Related]

  • 11. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb 14; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug-induced urticaria--activity of selected cytokines and acute phase proteins in plasma.
    Czelej D, Chodorowska G, Lechowska-Mazur I.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Feb 14; 58(1):38-42. PubMed ID: 15314956
    [Abstract] [Full Text] [Related]

  • 14. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
    Borazan A, Ustün H, Ustundag Y, Aydemir S, Bayraktaroglu T, Sert M, Yilmaz A.
    Mediators Inflamm; 2004 Jun 14; 13(3):201-4. PubMed ID: 15223612
    [Abstract] [Full Text] [Related]

  • 15. Drug-induced hyperergic vasculitis--activity of selected cytokines and acute phase proteins in plasma.
    Chodorowska G, Czelej D.
    Ann Univ Mariae Curie Sklodowska Med; 2003 Jun 14; 58(1):43-7. PubMed ID: 15314957
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
    Mysliwiec J, Oklota M, Nikolajuk A, Waligorski D, Gorska M.
    Immunol Invest; 2007 Jun 14; 36(3):247-57. PubMed ID: 17558708
    [Abstract] [Full Text] [Related]

  • 18. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I, Bokk A.
    Cytokine; 2006 Aug 14; 35(3-4):109-14. PubMed ID: 17008110
    [Abstract] [Full Text] [Related]

  • 19. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct 14; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 20. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients.
    Navarro JF, Mora C, Gómez M, Muros M, López-Aguilar C, García J.
    Nephrol Dial Transplant; 2008 Mar 14; 23(3):919-26. PubMed ID: 17911088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.